medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 2

<< Back Next >>

Gac Med Mex 2003; 139 (2)

Non-Hodgkin’s Lymphomas At Present

I. Introduction.
II. Classification of Lymphomas and Viablilty of Molecular Classification.
III. Novel Therapeutic Strategies in Lymphomas. Has th e Lymphoma Panorama Changed Over the Last Decade?.

Figueroa F, Silva-Moreno M, Rivas-Vera S, Sobrerilla P

Language: Spanish
References: 25
Page: 139-147
PDF size: 80.42 Kb.


Text Extraction

No abstract


REFERENCES

  1. Beutz M,Trumper I. Workshop report: Genetics and immunology of aggresive NHL. Ann Hematol 2001;8(Suppl 3):B 5-7.

  2. Ohno H, Ueda C, Akasaka T. The T (9,14) (p13,q32) translocation in B cell Non-Hodgkin's Lymphoma. Leukemia and Lymphoma 2000;36:435-445.

  3. Registro Histopatologico de Neoplasias Malignas en México, Dirección General de Epidemiologia, Secretaria de Salud, México 1996.

  4. Ekstrand BC, Horning SJ. Hodgkin's disease. Blood Reviews 2002;16:111-117.

  5. MauchPM, Duhmke E, Connors J, Pavlosky S. Treatmente of favorable prognosis stage I-II Hodgkin's Disease in Hodgkin's Disease eds Mauch PM,Armitage J, Diehl V,Hoppe R,Weiss L(Lippincott-Raven Philadelphia,PA 1999)pp 435-458.

  6. Yahalom J, Mauch PM. Early Stage Hodgkin's Disease.44th Annual Meeting Course 207 of ASTRO October 6-10 2002.New Orleans.

  7. Gospodarowics MK,Sutcliffe SB,Clark RM et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin;s disease treated with radiation alone.Int J. Radiat Oncol Biol Phys 1992;22:859.

  8. Linch DC, Gosden RG, tulandi T, Tan SL, HancocK SL. Hodgkin's Lymphoma: Choice of therapy and late complications Education Program Book.american Society of Hematology 2000.San Francisco Cal 205-21.

  9. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.

  10. Coiffier B, Lepage E, Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42.

  11. Vose JM, Colcher D, Gobar L, et al. Phase I/II trial of multiple dose 131 Iodine Mab LL2 ( CD22) in patients with recurrent Non-Hodgkin's Lymphoma. Leukemia and Lymphoma 2000;38(1-2):91-101.

  12. White CA, Halpern SE, Parker BA, et al. Radioimmunotherapy of relapsed B cell lymphoma with yttrium 90 anti idiotype monoclonal antibodies. Blood 1996;87:3640-3649.

  13. Brousse N. Histological classification of non-Hodgkin’s lymphomas. in Non-Hodgkin’s lymphomas edited by: Solal-Céligny P, Brousse N, Reyes F, Gissselbrecht C and Coiffier B; Editions Frison-Roche Paris 1993 pages: 95-100.

  14. Jaffe ES, Harris NL, Chan JKC et al. Proposed World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissue. Am J Surg Pathol 1997;21:114-21

  15. Harris NL, Jaffe ES, Diebold J et al. Lymphoma classification –from controversy to consensus: The REAL and WHO Classification of lymphoid neoplasms. Ann Oncol 2000;11(supl1):3-10.

  16. Jaffe ES, Harris NL, Stein H and Varian JW. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press. Lyon, France, 2001.

  17. Macintyre E, Willerford D, Morris SW. Non-Hodgkin’s lymphoma: Molecular Features of B Cell lymphoma. En American Society of Hematology. Education Program Book. Schechter GP, Berliner N, Telen MJ, Bajus JL (Eds.) San Francisco, Cal. 2000. pp 180-203.

  18. Harris NL, Stein H, Coupland S et al. New approaches to lymphoma diagnosis. En American Society of Hematology. Education Program Book. Schechter GP, Broudy VC, Williams ME, Bajus JL (Eds.) Orlando FL. 2001 pp. 194-220.

  19. 1· Armitage JO: Treatment of Non-Hodgkin Lymphoma. N Engl J Med 1993; 328:1023-1030.

  20. 2· Coiffer B, Lepage E, Brière J et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B cell lymphoma. N Engl J Med 2002; 346:235-42.

  21. 3· Horning SH, Glick JH, Kim K et al: Final report of E1384: CHOP versus CHOP

  22. 4· Marcus R, Hasgenbeek A, Eghbali H et al: Fludarabine versus CVP in newly diagnosed patients with stages III/IV non-Hodkin’s lymphoma. Final analysis of prospective randomized phase III intergroup study. Ann Oncol 2002; 13(Suppl.2):181

  23. 5· McLaughin P, Grillo-López AJ, Link BK et al: Rituximab chimerie anti CD-20 monoclonal antibody therapy for relapsed indolent lymphoma; half of patients respond to a four dose treatment program. J Clin Oncol 1998; 16:2825-33.

  24. 6· Miller TP, Leblanc M, Spier C et al: CHOP alone compared to CHOP plus radiotherapyfor early stage aggressive non-Hodgkin´s lymphoma; update of the Southewest oncology Group randomized trial. Program and abstracts of the 43rd Annual Meeting of the American Society of Hematology; December 711, 2001, Orlando, Florida. Abstract 3024

  25. 7· Pfreundschuh M, Trümper L, Kloess M et al: Two-weekly CHOP (CHOP-14): new standar regimen for patients withaggressive non-Hodgkin’slymphoma (NHL). Ann Oncol 2002; 13 (Suuppl.2) 81 (Abstr)




2020     |     www.medigraphic.com